newsfilter
← Latest News
GlobeNewswire·

Elicio Therapeutics and Angion Enter into Definitive Merger Agreement

Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio's proprietary lymph node-targeting Amphiphile (AMP) technologyLead program of the combined company will be ELI-002, a